5 big analyst AI moves: Nvidia guidance warning; Snowflake, Palo Alto upgraded
Investing.com - Raymond James raised its price target on Liquidia Technologies (NASDAQ:LQDA) to $41.00 from $33.00 on Wednesday, while maintaining a Strong Buy rating following the company’s second-quarter 2025 earnings report. The biotech company, now valued at $2.06 billion, has seen its stock surge over 104% year-to-date, according to InvestingPro data.
The firm cited a positive outlook for Yutrepia’s launch in PAH and PH-ILD, supported by strong metrics through August 8 that included over 900 unique patient prescriptions and more than 550 patient starts. The company maintains a healthy financial position with a current ratio of 2.93, indicating strong ability to meet short-term obligations.
Raymond James also highlighted positive data from the ASCENT study for Yutrepia at 16 weeks in PH-ILD patients, which showed a median improvement in 6-minute walk distance of 31.5 meters.
Liquidia plans to present additional data from the ASCENT study at the PHPN Symposium in September and at another medical conference in October, with an R&D day focused on L606 planned for fall 2025.
The firm increased its estimates for Yutrepia in both PAH and PH-ILD for fiscal year 2025 and beyond, citing clear demonstration of initial demand for the treatment.
In other recent news, Liquidia Technologies reported its second-quarter earnings for 2025, showcasing a remarkable revenue performance. The company achieved a revenue of $8.8 million, significantly exceeding the analysts’ forecast of $3.92 million, largely due to robust sales of its Eutropia product. Despite this impressive revenue beat, Liquidia posted a larger-than-expected loss per share of $0.49, compared to the anticipated $0.42. Additionally, Wells Fargo raised its price target for Liquidia to $31 from $25, maintaining an Overweight rating. This adjustment was influenced by the company’s strong product launch performance, which surpassed analyst expectations. Liquidia reported 94 unique patient prescriptions per week and 57 patient starts per week, contributing to the positive outlook. These developments reflect the company’s recent momentum and performance in the market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.